Considering T cell responses against Omicron spike, 31% (10/32) of patients with blood cancer had CD4+ T cell responses after three doses compared with 59% (19/32) after four doses (McNemar test, p = 0.0077) (Figure 1C), while 34% (11/32) had CD8+ T cell responses after three and 44% (14/32) after four doses (McNemar test, p = 0.51) (Figure 1D). This evidence concerns the gene CD4 and hematopoietic and lymphoid system neoplasm.